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Purpose: Chikungunya virus (CHIKV) causes endemic or
epidemic outbreaks of CHIKV fever, which is a mosquitoe-
transmitted viral disease in Africa, India, South-East Asia, and
recently Southern Europe. Currently, serological diagnostic
tests such as hemagglutination inhibition test (HI test),
in-house IgM capture enzyme-linked immunosorbent assays
(ELISA), and indirect immunofluorescence test were used for
diagnosis of chikungunya fever, which are based on whole
virus antigens. Materials and Methods: CHIKV E1, and E2
envelope proteins for the CHIKV-specific serodiagnostic
reagents for chikungunya fever were expressed in baculovirus
expression system. The seroreactivity of recombinant CHIKV
E1 and E2 envelope proteins were evaluated using sera panels
of patients from Laboratoire Marcel Merieux by indirect IgM
capture ELISA. Results: The recombinant CHIKV E1 and E2
envelope protein showed sensitivity of 77.5% and 90%,
respectively. The specificities of both CHIKV E1 and E2
envelope proteins were 100%. Conclusion: The recombinant
CHIKV E1 and E2 envelope proteins could be a useful
diagnostic reagent for CHIKV infection.
Key Words: Chikungunya virus, E1 and E2, envelope protein,
baculovirus, indirect IgM ELISA
INTRODUCTION
Chikungunya (CHIK) fever is a mosquito-borne
viral disease of humans, which is characterized by
high fever, rash and polyarthralgia by Chikungunya
virus (CHIKV) infection.
1 CHIKV is transmitted to
humans mainly by Aedes (Ae.) aegypti and Ae.
albopictus mosquitoes.
2 CHIKV, which was first
isolated from the serum of a febrile human in
Tanganyika (Tanzania) in 1953,
3 has caused a
number of outbreaks in Africa, India, South East
Asia, and Southern Europe.
4,5 Recently, a major
outbreak occurred in the western part of the
Indian Ocean islands, and La Reunion island in
2005 - 2006. In that outbreak, 270,000 cases of
CHIKV infection were reported (34% of the
population).
6 In India in 2006, there was a large
outbreak of CHIKV infection with 1.39 million
CHIKV reported cases.
1,4,7 Increased travel and
trade has introduced these vectors to all continents
with an increasing risk for globalization of these
vector-borne viral diseases.
8
The major clinical symptom of CHIKV infection
is febrile illness, which is clinically similar to
symptoms of Dengue virus infection.
9 Both these
viral diseases are transmitted by the same species
of the mosquitoes Ae. aegypti and Ae. ablopictus,
and mixed outbreak of CHIKV with sporadic
cases of Dengue virus has been reported in
Andhra Pradesh state, India.
10 However, unlike
Dengue virus infection, CHIKV infection is rarely
fatal and usually does not require close clinical
supervision. Therefore, the ability to distinguish
CHIKV infection from Dengue virus infection
would be important to launch control measures,
particularly in areas where Dengue virus infection
is endemic or epidemic.
CHIKV is an enveloped, positive strand RNA
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virus, which is an alphavirus of the Togaviridae
family.
9 The genome of CHIKV consists of a
linear, positive-sense, single-stranded RNA of
approximately 11.8 kb, and contains structural
genes that encode three structural proteins; E1
and E2 of envelope, and nucleocapsid protein.
11,12
The CHIKV envelope protein E1 and E2 are
components of spikes, which composed of triplets
of heterodimer of E1 and E2 glycoproteins, and
cover the viral surface in the form of membrane-
anchored types. The viral spike proteins facilitate
attachment to cell surfaces and viral entry into the
cells. The E1 envelope protein is a class II fusion
protein that mediates low pH-triggered membrane
fusion during virus infection. The E2 envelope
protein is a type I transmembrane glycoprotein
and has been known to be responsible for receptor
biding during the course of alphavirus cycle.
13,14
Current main laboratory diagnosis for CHIKV
infection is virus isolation, serological tests and
molecular method, using reverse transcriptase
polymerase chain reaction (RT-PCR). The serologi-
cal tests include hemagglutination inhibition test
(HI test) and ELISA detecting IgM antibodies of
CHIKV. HI test is a simple and rapid test,
however the results can be difficult to interpret
due to cross-reactivity with other viruses.
9,15
ELISA is an another popular method to detect
viral antigen-specific antibodies because of its
high sensitivity and specificity. Presently, the
whole virus antigens in crude form have been
used as a diagnostic reagent for CHIKV diagnosis.
Therefore, CHIKV-specific antigen is urgently
needed as a diagnostic reagent for CHIK fever.
In this study, we expressed the CHIKV envelope
proteins, E1 and E2, in the baculovirus expression
system, and evaluated the seroreactivity of the
recombinant envelope proteins as a diagnostic
reagent for CHIKV infection using ELISA.
MATERIALS AND METHODS
Sera panel
The evaluation panel for CHIKV was purchased
from Laboratoire Marcel Merieux (Lyon, France),
consisting of 40 positive and 20 negative serum
samples, based on the anti-CHIKV IgM antibody
titer by IgM capture ELISA (cut off value, A450=
0.15, Fig. 3). As a negative control, 20 normal
serum samples were collected from healthy
Koreans who have never traveled to endemic or
epidemic areas of CHIKV or Dengue virus. To
check the cross-reactivity with Dengue virus
infection, twenty Dengue fever-positive serum
samples were kindly provided from Arboviruses
Laboratory, National Institute of Hygiene and
Epidemiology, Hanoi, Vietnam.
Construction of baculovirus transfer vector
containing CHIKV E1 and E2 envelope proteins
In order to clone the CHIKV envelope protein
genes, E1 and E2, CHIKV (strain TSI-GSD-218)
was propagated in C6/36 cells, and CHIKV
genomic total RNA was extracted from CHIKV-
infected C6/36 cells using an RNeasy mini kit
(Qiagen Inc., Valencia, CA, USA). The cDNA
synthesis and amplification of the envelope genes
were performed using RT-PreMix (Bioneer Inc.,
Seoul, Korea). The CHIKV envelope protein genes,
E1 and E2 were amplified using the following
primers encoding appropriate restriction enzyme
sites: E1 (sense, 5'-GGATCCCCGAACACGGTG
GGAGTACCG-3'; antisense, 5'-AAGCTTTCCCGT
GATCTTCTGCACCCAT-3') and E2 (sense, 5'-G
GATCCCCATACTTAGCTCACTGTCCCG-3';
antisense, 5'-AAGCTTAGTCATAGTGGGGTACA
GCTCA-3'). The PCR-amplified CHIKV envelope
protein genes containing enzyme sites were ligated
with pCR2.1 Topo vector (Invitrogen, Carlsbad,
CA, USA), and then the CHIKV envelope protein
genes were subcloned into the baculovirus vector
pFastBac HT (Invitrogen, Carlsbad, CA, USA). The
resulting plasmid pFast HT-CHIKV-E1/-E2 were
used to generate recombinant viruses.
Generation of recombinant baculovirus
Recombinant viruses were generated as de-
scribed.
16,17 Briefly, Sf900 II SFM cells (Sf9, Invitro-
gen, Carlsbad, CA, USA) were transfected with
the recombinant transfer vector pFastBac HT-
CHIKV-E1/-E2 to generate recombinant baculo-
virus. As a control, pFastBac HT-CAT vector was
transfected into cells. Liposome-mediated gene
transfer was employed with Cellfectin (Invitrogen,Byungki Cho, et al.
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Carlsbad, CA, USA). A few plaques were picked,
and recombinant viruses were purified by plaque
assay and confirmed by PCR amplification and
Western blot analysis.
Expression analysis and immunoblotting
Sf9 cells were infected with recombinant
baculoviruses at a multiplicity of infection of 5 : 1
PFU: cell and incubated at 27°C. Three days
post-infection, cells were harvested and whole-cell
lysates were analyzed by a discontinuous sodium
dedecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) system, and the gels were stained
with Coomassie blue. Proteins resolved by SDS-
PAGE were electrophoretically transferred onto a
nitrocellulose membrane for Western blot
analysis.
18 The membrane was incubated in PBS
containing 2% skim milk and then reacted with
1 :100 dilution of CHIKV IgM positive serum,
which was prepared by pooling 40 CHIKV IgM
positive sera. After 1 hour, the membrane was
washed several times and subsequently treated
with horseradish peroxidase (HRP) conjugated
goat anti-human IgM antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at a 1 : 2,000
dilution for 1 hour at room temperature. Protein
binding was detected using the Amersham
Biosciences ImmunoBlot System (Amersham
Pharmacia Biotech, Stockholm, Sweden).
Affinity purification of the recombinant CHIKV
envelope proteins
A high-yield, homogenous preparation of
CHIKV envelope proteins, E1 and E2, were obtained
by using the nikel-nitrilotriacetic acid (Ni-NTA)
resin, according to the standard procedures des-
cribed by the manufacturer (Clonteck, Mountain
View, CA, USA). Briefly, recombinant baculovirus-
infected Sf9 cell lysates were pelleted, and the
supernatants were added to the equilibrated Ni-
NTA agarose in a 1: 10 volume ratio. The bead
slurry was then washed with 10 volumes of 50 mM
sodium phosphate, 300 mM NaCl, 10% glycerol,
and 20 mM imidazole (pH 8.0). The CHIKV
envelope proteins were then eluted with 300 or
500 mM imidazole in 50 mM sodium phosphate,
300 mM NaCl, and 10% glycerol (pH 6.0).
Indircet anti-CHIKV IgM ELISA
Enzyme-linked immunosorbent assays (ELISA)
were performed to evaluate the reactivity of
recombinant CHIKV envelope proteins, E1 and E2
to anti-CHIKV IgM antibodies as described
before.
20,21 Ninety-six well enzyme immunoassay
(EIA) plates (Costar, Cambridge, MA, USA) were
coated overnight with serial dilutions of
recombinant CHIKV envelope proteins, E1 or E2
(1, 2, 4, 8 g/mL) in a volume 100 μ L of poly μ -
carbonate buffer (pH 9.2) at 4°C. Plates were then
washed and blocked with PBS (pH 7.4) containing
1% BSA for 1 hour at 37°C. Serum samples were
diluted in PBS containing 1% BSA (1 : 100) and
were then added to the wells and incubator for 1
hour at 37°C. The bound antibodies were detected
with horseradish peroxidase-conjugated mouse
anti-human IgM antibody (1 : 3,000 dilution,
Standard Diagnostics, Yongin, Korea). The plates
were washed at least four times with PBS
containing 0.05% Tween 20 between each step. An
enzyme substrate TMB (Sigma Chemical Co., St
Louis, MO, USA) was added to the wells and
incubated for 30 min. The reaction was stopped
by adding 1.5 N H2SO4, and the absorbance was
read at 450 nm using an automatic ELISA reader
(Molecular Devices, Biotek Instruments, Hyland
Park, VA, USA). The absorbance ratio of anti-
CHIKV positive to negative serum to the
recombinant envelope protein (P/N ratio) was
calculated as follows; A450 of positive serum/
A450 of negative serum.
Statistical analysis
Differences between experimental groups were
analyzed using the GraphPad Prism (ver. 4)
program. Differences were considered significant
when p was < 0.05.
RESULTS
Cloning the CHIKV envelope protein genes, E1
and E2, and construction of recombinant
baculovirus
The CHIKV envelope protein genes, E1 and E2,A
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were amplified and the amplified envelope genes
were ligated with pCR 2.1 Topo vector PCR. The
sequences of CHIKV envelope protein genes, E1
and E2, were confirmed (data not shown). The
each envelope protein gene was subcloned into
the baculovirus vector pFastBac HT from pCR 2.1
Topo vector after enzyme digestion.
Expression of CHIKV envelope proteins in Sf9 cell
cultures
The CHIKV envelope protein gene constructs
(pFastBac HT-CHIKV-E1/-E2) were expressed in
Sf9 cells. In order to validate the expression of
CHIKV envelope proteins, E1 and E2, infected
cells were harvested 24, 48, and 72 hours post-
infection, whole-cell lysates were analyzed by
SDS-PAGE, and the gels were stained with
Coomassie blue (Fig. 1). The expression level of
recombinant CHIKV envelope proteins peaked at
72 hours post-infection (data not shown). CHIKV
E1 and E2 envelope protein with molecular mass
of 44 kDa and 40 kDa, respectively, were expressed
in Sf9 cells infected with recombinant baculovirus
(Fig. 1). These corresponding protein bands of
CHIKV E1 and E2 envelope proteins were
observed in the cell lysates infected with each
recombinant baculovirus and in the purified
proteins infected (lanes 2 and 3 in Fig. 1). The
each corresponding protein was not present in
mock-infected cells (lane 1 in Fig. 1). The identity
of the recombinant CHIKV envelope proteins, E1
and E2, was confirmed by Western blot analysis
using pooled anti-CHIKV positive serum (lane 4
in Fig. 1).
These results demonstrate that the expression
and purification of CHIKV envelope proteins, E1
and E2, was successfully done via the baculovirus
expression system.
Titration of recombinant CHIKV envelope protein,
E1 and E2, for detection of anti-CHIKV IgM
antibodies by indirect ELISA
The recombinant baculovirus-expressed CHIKV
envelope protein, E1 and E2, were titrated to
detect anti-CHIKV IgM antibodies using indirect
ELISA. In order to determine the optimal concen-
tration of recombinant CHIKV envelope proteins,
each recombinant envelope protein was serially
diluted from 0.5 to 8.0 g/mL (from 50 to 800 μ ng/
well, respectively), and CHIKV envelope proteins,
E1 and E2-specific IgM antibodies, were detected
using pooled anti-CHIKV positive or negative
Fig. 1. Analysis of expression of CHIKV E1 (A) and E2 (B) envelope protein in Sf9 cells. Sf9 cell lysates were analysed
by SDS-PAGE, and the gel was stained with Coomassie blue (lanes 1 to 3) or analysed by Western blot with pooled
anti-CHIKV positive serum (lane 4). M; Prestained protein marker, lane 1; lysate of Sf9 cells infected with mock-vector,
lane 2; lysate of Sf9 cells infected with recombinant virus containing CHIKV E1 (A) or E2 (B) envelope protein gene,
lane 3; purified recombinant CHIKV E1 (A) or E2 (B) envelope protein, lane 4; Western blot analysis with pooled
anti-CHIKV positive serum. CHIKV, chikungunya virus.
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serum samples. As shown in Fig. 2, as little as 50
ng/well (0.5 g/mL) of recombinant E1 or E2 μ
protein produced an ELISA signal for pooled
anti-CHIKV positive serum. The highest ratio of
absorbance value of CHIKV positive to negative
serum (P/N ratio) for recombinant E1 protein was
20 at the level of 200 ng/well (2.0 g/mL) of E1 μ
envelope protein (Fig. 2A). Interestingly, the highest
P/N ration for recombinant CHIKV E2 envelope
protein was 62.5 at the level of 100 ng/well (1.0
g/mL) of E2 envelope protein (Fig. 2B), which μ
was considered to be an optimal concentration of
the recombinant E1 and E2 envelope protein for
evaluation of CHIKV serum samples, because
absorbance value was high at the level of 100
ng/well (1.0 g/mL) of E1 envelope protein even μ
though P/N ratio of E1 protein was the highest,
200 ng/well. In the following experiments, there-
fore, this quantity of recombinant protein was
used.
Evaluation of the recombinant CHIKV envelope
protein E1 and E2 using indirect IgM capture
ELISA
The recombinant CHIKV envelope proteins, E1
and E2, were evaluated for the detection of
anti-CHIKV IgM antibodies using ELISA. Sixty
anti-CHIKV serum samples (40 positive and 20
negative) from Laboratoire Marcel Merieux (LMM,
Lyon, France) were used to evaluate the recom-
binant CHIKV envelope proteins as a diagnostic
reagent for CHIKV infection. To check the
cross-reactivity of the CHIKV envelope proteins
with Dengue virus infection, twenty anti-Dengue
virus positive serum samples were also included.
As a negative control of CHIKV and Dengue virus
infection, twenty normal serum samples from
healthy Koreans were included.
As shown in Fig. 3, the mean absorbance values
for forty anti-CHIKV positive serum samples were
approximately 0.88 and 1.23 for the recombinant
CHIKV envelope proteins E1 and E2, respectively.
The absorbance values of anti-CHIKV positive
serums for CHIKV E2 envelope protein were
significantly higher than those for CHIKV E1
envelope protein (p < 0.001), and there was
significant correlation between absorbance values
Fig. 2. Detection of anti-CHIKV IgM antibodies by recom-
binant CHIKV E1 (A) and E2 (B) envelope protein-based
ELISA. Each well of a microtiter plate was coated with
various amounts of recombinant CHIKV E1 and E2 envelope
protein and evaluated for their reactivity with pooled
anti-CHIKV positive or negative serum. Absorbance was
read at 450 nm. The P/N ratio is A450 of positive serum/
A450 of negative serum. CHIKV, chikungunya virus.
A
B
Fig. 3. The seroreactivity of the recombinant CHIKV E1
and E2 envelope proteins using indirect IgM ELISA. Forty
anti-CHIKV positive serum samples were used to evaluate
the seroreactivity of the recombinant CHIKV E1 ( ) and E2
( ) envelope proteins. The absorbance was read at 450 nm.
IgM capture ELISA data (O) were supplied from Labora-
toire Marcel Merieux. CHIKV, chikungunya virus.Seroreactivity of Chikungunya Virus E1 and E2 Envelope Proteins
Yonsei Med J Vol. 49, No. 5, 2008
of anti-CHIKV IgM positive serum samples for
recombinant CHIKV E1 and E2 envelope protein
(r = 0.8328, p < 0.001). However, there was no
significant correlation between the absorbance
values of 40 anti-CHIKV IgM positive serum
samples for recombinant CHIKV E1 or E2, and
absorbance values of 40 anti-CHIKV IgM positive
serum samples from Laboratoire Marcel Merieux
(Lyon, France).
The reactivity of the recombinant CHIKV E1
and E2 envelope proteins was very low (A450 <
0.2) for twenty anti-CHIKV negative serum
samples and twenty normal control serum
samples derived from healthy Koreans. The
cross-reactivity of the recombinant CHIKV E1 and
E2 envelope proteins was very low for all twenty
Dengue virus samples (A450 < 0.2).
The sensitivities of the recombinant CHIKV E1
and E2 envelope proteins for anti-CHIKV positive
serum samples were 77.5% and 90%, respectively
(based on the cut off values, A450 = 0.2) (Table 1).
The specificities of the recombinant CHIKV E1
and E2 envelope proteins for anti-CHIKV negative
serum samples were 100% (Table 1).
These results indicate that the recombinant
CHIKV E1 and E2 envelope proteins were strongly
reactive towards anti-CHIKV IgM antibodies, and
showed a low cross-reactivity with anti-Dengue
virus IgM antibodies.
DISCUSSION
CHIKV and Dengue virus clinically cause similar
febrile disease, but the prognosis of Dengue virus
infection is more severe. The outbreaks by these
viruses infection occur often within the similar
geographical area and same vectors, most of
which are Ae. aegypti. Thus, the laboratory
confirmation between CHIKV and Dengue virus
infection is essential in order to launch control
measures when an epidemic or endemic outbreak
occurs. Current serological laboratory diagnosis
for CHIKV is based on HI test, ELIAS, and
indirect immunofluorescence test. HI test is a
simple and rapid test
9,15,22 and ELISA is a popular
serological method with high sensitivity and
specificity.
20,21,23 Currently, indirect immunofluor-
escence test has been developed as commercial
kit.
24 However, the whole virus antigens in the
crude form were used as a diagnostic reagent for
CHIKV in these immunological methods.
Therefore, in this study, CHIKV E1 and E2
envelope proteins were expressed in a baculovirus
expression system as CHIKV-specific diagnostic
reagents. The seroreactivity of CHIKV E1 and E2
envelope proteins was evaluated using anti-
CHIKV positive and negative serum samples, and
the cross-reactivity of CHIKV E1 and E2 envelope
protein with Dengue virus was evaluated using
anti-Dengue virus serum samples. The sensitivities
of the recombinant CHIKV E1 and E2 envelope
proteins for anti-CHIKV positive serum samples
were 77.5% and 90%, respectively (based on the
cutoff value A450 < 0.2). The specificities of the
recombinant CHIKV E1 and E2 envelope proteins
were 100% for anti-CHIKV negative serum samples.
The sensitivity of CHIKV E2 envelope protein was
Table 1. Agreement, Sensitivity, and Specificity of Anti-CHIKV IgM Indirect ELISA Using the Recombinant CHIKV
E1 and E2 Envelope Proteins with Anti-CHIKV IgM Capture ELISA from LMM
IgM capture
ELISA (LMM)*
Indirect IgM ELISA
CHIKV E1 CHIKV E2
No. of
positive
No. of
negative
Sensitivity
(%)
Specificity
(%)
No. of
positive
No. of
negative
Sensitivity
(%)
Specificity
(%)
Positive (n = 40) 31 9
77.5% 100%
36 4
90% 100%
Negative (n = 20) 0 20 0 20
CHIKV, chikungunya virus; LMM, Laboratoire Marcel Merieux.
*Defined as positive based on the cut off values, A450 = 1.5.
Defined as positive based on the cut-off values, A450 = 0.2.Byungki Cho, et al.
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higher than that of CHIKV E1 envelope protein,
even though there was a highly significant
correlation in the seroreactivity between CHIKV
E1 and E2 envelope protein for anti-CHIKV
positive serum samples (p < 0.001). This difference
between CHIKV E1 and E2 envelope protein
might be explained by the fact that CHIKV E1
envelope protein is buried almost in the virus
structure,
25 which may give CHIKV E1 envelope
protein less chance to exposure to host immune
system. The sensitivity and specificity of the
recombinant CHIKV E2 envelope protein to detect
anti-CHIKV IgM antibodies using indirect IgM
ELISA were similar to the sensitivity (96.9%) and
specificity (98.3%) using indirect immunofluores-
cence test.
24 These results indicate that recom-
binant CHIKV E2 envelope protein is also
immunogenic as whole virus antigens which was
used as a serodiagnostic reagent in the indirect
immunofluorescence test. The absorbance values
of anti-CHIKV positive serum samples to CHIKV
E1 and E2 envelope proteins appear to be higher
than the absorbance values of anti-CHIKV
positive serum samples from Laboratoire Marcel
Merieux (Lyon, France), even though the direct
comparison of these data is not possible because
different ELISA methods were used. The
cross-reactivity of the recombinant CHIKV E1 and
E2 envelope proteins with twenty Dengue positive
serum samples was not observed.
In the endemic or epidemic areas of CHIK
fever, previous infection of CHIKV could induce
seroreactivity with CHIKV antigens, because
anti-CHIKV IgM antibodies persist more than one
year. Further assessment using the serum samples
which are derived from both previous and
currently CHIKV-infected people is needed.
In next extensive studies, cross-reactivity of
recombinant CHIKV E1 and E2 envelope proteins
also needs to be evaluated with a closely related
virus, o’nyong-nyong (ONN) virus, which is a
member of the genus Alphavirus in the family
Togaviridae,
26 and cause a febrile symptom similar
to CHIKV and Dengue virus infection, even
though ONN virus is transmitted by anopheline
mosquitoes, typically Anopheles (An.) funestus and
An. Gambiae and there is a district phylogenetic
difference between ONN virus and CHIKV.
27
These results suggest that the recombinant
CHIKV E1 and E2 envelope proteins have a
potential as diagnostic reagents of serological
diagnostic methods such as ELISA, immunochro-
matographic assay and indirect immunofluores-
cence because of high levels of sensitivity and
specificity towards CHIK fever.
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